Same Indication

Ipilimumab vs Rosuvastatin

Ipilimumab vs Rosuvastatin: Overview

This comparison examines the pharmacological differences between Ipilimumab and Rosuvastatin.

Mechanism of Action

Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Rosuvastatin: Competitive inhibitor of HMG-CoA reductase.

Pharmacokinetics

Half-life: Ipilimumab β€” 14.7 days; Rosuvastatin β€” 19 hours.

Chemical Properties

Molecular Formula: Rosuvastatin β€” C22H28FN3O6S.

Molecular Weight: Rosuvastatin β€” 481.5390 g/mol.

Type: Ipilimumab β€” Antibody; Rosuvastatin β€” Small molecule.